Leishmania donovani-derived lipophosphoglycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamsters (Mesocricetus auratus) and BALB/c mice against Leishmania donovani

Onderstepoort Journal of Veterinary Research

Volumn 70, Issue 4, 2003, Pages 255-263

  Tonui, W K ^a   Mpoke, S S ^a   Orago, A S ^b   Turco, S J ^c   Mbati, P A ^d   Mkoji, G M ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b KENYATTA UNIVERSITY   (Kenya)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF LIMPOPO   (South Africa)

Author keywords

Bacille Calmette Gu rin; BALB c mice; Leishmania donovani; Lipophosphoglycan; Syrian golden hamsters

Indexed keywords

BCG VACCINE; LIPOPHOSPHOGLYCAN; PROTOZOAL VACCINE; TRIPLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; INFECTION RISK; LEISHMANIA DONOVANI; MOUSE; MOUSE STRAIN; NONHUMAN; RAT; SPLEEN ABSCESS; SYRIAN HAMSTER; TH1 CELL; VISCERAL LEISHMANIASIS;

ANIMALIA; CRICETINAE; LEISHMANIA DONOVANI; MESOCRICETUS AURATUS; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG;

EID: 1542475418     PISSN: 00302465     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. CARVALHO, E.M., BADARO, R., REED, S.G., JONES, T.C. & JOHNSON, W.D. 1985. Absence of gamma-interferon and interleukin-2 production during active visceral leishmaniosis. Journal of Clinical Investigations, 76:2066-2069.
2. CHULAY, J.D. & BRYCESSON, A.D.M. 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniosis. American Journal for Tropical Medicine and Hygiene, 32:475-479.
3. CONNELL, N.D., MEDINA-ACOSTA, E., MCMASTER, W.R., BLOOM, B.R. & RUSSELL, D.G. 1993. Effective immunization against cutaneous leishmaniosis with recombinant Bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proceedings of the National Academy of Sciences USA, 90:11473-11477.
4. ELHAY, M., KELLEHER, M., BACIC, A., MCCONVILLE, M.J., TOLSON, D.L., PEARSON, T.W. & HANDMAN, E. 1990. Lipophosphoglycan expression and virulence in ricin-resistant variants of Leishmania major. Molecular Biochemical Parasitology, 40:255-268.
5. GAJEWSKI, F.T., SCHELL, R.S., NAU, G. & FITCH, W.F. 1989. Regulation of T-cell activation: difference among T-cell subsets. Immunological Reviews, 111:79-110.
6. GICHERU M., OLOBO, J., ANJILI, C., ORAGO, A.S., MODABBER, F. & SCOTT, P. 2001. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a Type1 immune response but are not protected against infection challenge. Infection and Immunity, 69:245-251.
7. HANDMAN, E. 2001. Leishmaniosis. Current status of vaccine development. Clinical Microbiology Reviews, 14:229-243.
8. HANDMAN, E., SYMONS, F.M., BALWIA, T.M., CURTIS, J. & SCHEERLINCK, J.P.Y. 1995. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infection and Immunity, 63:4261-4267.
9. HANDMAN, E. & MITCHEL, G.F. 1985. Immunization with Leishmania receptor for macrophages protective against cutaneous leishmaniosis. Proceedings of the National Academy of Sciences USA, 82: 5910-5914.
10. INGONGA, P., MBATI, P.A., ANJILI, C.O., MUTANI, A., WISHITEMI, B., ODONGO, S., ROBERT, L.L. & GITHURE, J.I. 1996. The effect of immune sera from hamsters immunized with sand fly gut and whole body extract antigens on the fecundity and mortality of Phlebotomus duboscqi (Diptera: Psychodidae). Acta Tropica, 60:269-279.
11. JARDIM, A., TOLSON D.L., TURCO, S.J., PEARSON T.W. & OLAFSON, R.W. 1991. The Leishmania donovani lipophosphoglycan T-lymphocyte-reactive component is a tightly associated protein complex. Journal of Immunoology, 147: 3538-3544.
12. KEMP, M. 1997. Regulator and effector functions of T-cell subsets in human Leishmania infections. Acta Pathologica, Microbiologica et Immunologica Scandinavica Suppl., 68: 1-33.
13. KEMP, M., KURTZHALS, J.A., BENUTZEN, K., POULSEN, L.K., HANSEN, M.B., KOECH, D.K., KHARAZMI, A. & THEANDER, T.G. 1993. Leishmania donovani-reactive Th1-and Th2-like T-cell clones from individuals who have recovered form visceral leishmaniosis. Infection and Immunity, 61: 1069-1073.
14. KEMP, M., THEANDER, T.G., HANDMAN, E., HEY, A.S., KURTZHALS, J.A.L., HVIID, L., SØRENSEN, A.L., WERE, O.B., KOECH, D.K. & KHARAZMI, A. 1991. Activation of human T-lymphocytes by Leishmania lipophosphoglycan. Scandinavian Journal of Immunobgy, 33:219-224.
15. KHALIL, E.A., HASSAN, A.M., ZIJLSTRA, E.E., MUKHTAR, M.M., GHALIB, H.W., BREYMA, M., IBRAHIM, M., KAMIL, A., ELSHEIKH, M., BABIKER, A. & MODABBER, F. 2000. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniosis: a randomised, double-blind, BCG-controlled trial in Sudan. The Lancet, 356:1565-1569.
16. MBATI, P.A., ABOK, K., ORAGO, A.S., ANJILI, C.O., KAGAI, J.M., GITHURE, J.I. & KOECH, D.K. 1994. Establishment of appropriate inoculum dose of Leishmania donovani promastigotes required to establish a visceral infection in laboratory rodent models. Africa Journal of Health Sciences, 1: 165-168.
17. MBATI, P.A., ANJILI, C.O., LUGALIA, R., MWANYUMBA, P., TONUI, W.K., ROBERT, L.L. & GITHURE, J.I. 1995. Experimental immunization against cutaneous leishmaniosis using Leishmania major sub-cellular fractions alone or in combination with Phlebotomus duboscqi gut antigens. East African Medical Journal, 72:519-522.
18. MCCONVILLE, M.J., BACIC, A., MITCHELL, G.F. & HANDMAN, E. 1987. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniosis contain an alkyglycerophospholinositol lipid anchor. Proceedings of the National Academy of Sciences USA, 84:8941-8945.
19. MCNEELY, T.B. & DOYLE, P.S. 1996. Isolation of lipophosphoglycans from Leishmania donovani amastigotes. Archives of Biochemistry and Biophysics, 334:1-8.
20. MENDONCA, S.C., RUSSELL, D.G. & COUTINHO, S.G. 1991. Analysis of the human T-cell-responsiveness to purified antigens of Leishmania; lipophosphoglycan (LPG) and glycoprotein (GP63). Clinical Experimental Immunology, 83:472-478.
21. MITCHELL, G.F. & HANDMAN, E. 1986. The glycoconjugate derived from a Leishmania major receptor for macrophages is a suppressonic, disease-promoting antigen in murine cutaneous leishmaniosis. Parasite Immunology, 8:255-263.
22. MOODY, D.B., ULRICH, T., MUHLECKER, W., YOUNG, D.C., GURCHA, S.S., GRANT, E., ROSAT, J.P., BRENNER, M.B., COSTELLO, C.E., BESRA, G.S. & PORCELLI, S.A. 2000. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature, 404:884-888.
23. ORLANDI, P.A. & TURCO, S.J. 1987. Structure of the lipid moiety of Leishmania donovani lipophosphoglycan. Journal of Biological Chemistry, 262:10384-10391.
24. PEARSON, R.D., COX, G., JERONIO, S.M.B., CASTRACHE, J., DREW, J.S., EVANS, T. & EDUARDO DE ALENCAR, J. 1992. Visceral leishmaniosis: a model for infection-induced cachexia. American Journal for Tropical Medicine and Hygiene, 47:8-15.
25. RUSSELL, D.G. & ALEXANDER, J. 1988. Effective immunization against cutaneous leishmaniosis with defined membrane antigens reconstituted in liposomes. Journal of Immunology, 140:1274-1279.
26. RUSSO, D.M., TURCO, S.J., BURNS, J.M. JR & REED, S.G. 1992. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. Journal of Immunology, 148:202-207.
27. SHARIFI, I., FEKRI, A.R., AFLATONIAN, M.R., KHAMESIPOUR, A., NADIM, A., MOUSAVI, M.R., MOMENI, A.Z., DOWLATI, Y., GODAL, T., ZICKER, F., SMITH, P.G. & MODABBER, F. 1998. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniosis in Bam, Iran. The Lancet, 351: 1540-1543.
28. SIELING, P.A., OCHOA, M.T., JULLIEN, D., LESLEI, D.S., SABET, S., ROSAT, J.P., BURDICK, A.E., REA, T.H., BRENNER, M.B., PORCELLI, S.A. & MODLIN, R.L. 2000. Evidence of human CD4+ T-cells in the CD1-restricted repertoire: derivation of mycobacteria-reactive T-cells from leprosy lesions. Journal of Immunology, 164:4790-4796.
29. STREIT, J.A., RECKER, T.J., DONELSON, J.E. & WILSON, M.E. 2000. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Experimental Parasitology, 94:33-41.
30. SUGITA, M., MOODY, D.B., JACKMAN, R.M., GRANT, E.P., ROSAT, J.P., BEHAR, S.M., PETER, S.J. PORCELLI, S.A. & BRENNER, M.B. 1998. CD1 - a new paradigm for antigen presentation and T-cell activation. Clinical Immunology and Immunopathology, 87:8-14.
31. TONUI, W.K. 1999. Leishmania transmission-blocking vaccines: a review. East African Medical Journal, 76:93-96.
32. TONUI, W.K., MBATI, P.A., ANJILI, C.O., ORAGO, A.S., TURCO, S.J., GITHURE, J.I. & KOECH, D.K. 2001a. Transmission blocking vaccine studies in leishmaniosis. I: Lipophosphoglycan (LPG) is a promising transmission blocking vaccine candidate against cutaneous leishmaniosis East African Medical Journal, 78:84-89.
33. TONUI, W.K., MBATI, P.A., ANJILI, C.O., ORAGO, A.S., TURCO, S.J., GITHURE, J.I. & KOECH, D.K. 2001b. Transmission blocking vaccine studies in leishmaniosis: II. Effect of immunization using L. mayor-derived 63 kilo Dalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice. East African Medical Journal, 78:90-92.
34. TONUI, W.K., NGUMBI, P., MPOKE S., ORAGO, A.S., MBATI, P.A., TURCO, S.J. & MKOJI, G.M. 2003. Leishmania major-Phlebotomus duboscqi interactions: inhibition of anti-LPG antibodies and characterization of two proteins with shared epitopes. East African Medical Journal, in press.
35. TURCO, S.J. 1988. The lipophosphoglycan of Leishmania. Parasitology Today, 4:255-257.
36. VOLLER, A., BARTLETT, A. & BIDWELL, D.E. 1976. Enzyme-linked immunoassays for parasitic disease. Transactions of the Royal Society for Tropical Medicine and Hygiene, 70:98-106.
37. WEINTRAUB, J. & WEINBAUM, F.I. 1977. The effect of BCG on experimental cutaneous leishmaniosis in mice. Journal of Immunology, 118:2288-2290.
38. WHITE, A.C., JR & MCMAHON-PRATT, D. 1990. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine. Journal of Infectious Diseases 161:1313.
39. YANG, D.M., ROGERS, M.V. & LIEW, F.Y. 1991. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology, 72:3-9.